Photo taken from Edward Cliff/LinkedIn
Oct 17, 2023, 01:19
Edward Cliff: POLARIX trial of antibody-drug conjugate polatuzumab vedotin in diffuse large B-cell lymphoma.
Edward Cliff, Postdoctoral Research Fellow at Harvard Medical School, shared on LinkedIn:
“Just out in Blood: David Russler-Germain, Nancy Bartlett and I delve into the cell of origin subgroup analysis from the POLARIX trial of antibody-drug conjugate polatuzumab vedotin in diffuse large B-cell lymphoma, and explain why we think this signal is confirmatory rather than hypothesis-generating.
We highlight the pre-clinical, observational and clinical trial evidence all points to the same pattern: polatuzumab seems to work better in ABC-type Diffuse Large B-Cell Lymphoma.”
To read the paper click here.
Source: Edward Cliff/LinkedIn
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023